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INTRODUCTION
A growing number of adult and pediatric studies have dem-
onstrated that human immunodeficiency virus (HIV) type 1
(HIV-1) RNA levels have importance in determining the risk
of both disease progression and the transmission of infection
from mother to infant (3, 4, 7, 9, 12, 15, 16, 19, 26–28, 34–36).
However, there has been concern that the different assays for
determination of HIV-1 RNA levels and the different tech-
niques used for specimen handling and processing in those
investigations may make interpretation of findings across stud-
ies difficult. Issues concerning specimen handling prior to test-
ing of plasma for HIV-1 RNA levels are important since some
reports suggest that variations in specimen handling may pro-
foundly affect the detection of and quantification of plasma
HIV-1 RNA (18, 19).
A workshop sponsored by the National Institute of Allergy
and Infectious Diseases National Institutes of Health and en-
titled Technology Utilization for HIV-1 Blood Evaluation and
Standardization in Pediatrics: A Special Emphasis on Plasma
RNA Assays was held on 17 and 18 June 1996 in the Wash-
ington, D.C., area to address these issues. The primary purpose
of that workshop was to convene a group of expert investiga-
tors from academia, government, and industry to develop rec-
ommendations on the most appropriate specimen collection,
processing, storage, and shipping methods for blood collected
in pediatric HIV-1 studies in both national and international
settings, with an emphasis on what was required if quantitative
plasma HIV-1 RNA assays were to be used in the investiga-
tions. Invited investigators presented data from studies with
specimens that were acquired from adults and children and
that addressed pertinent specimen-handling issues.
The highlights of the proceedings of the workshop are pre-
sented in this report. The information includes biological and
specimen-handling factors that may affect the results of assays
for plasma HIV-1 RNA levels and summaries of recommen-
dations for the most appropriate specimen-handling methods
for pediatric studies in both the national and the international
settings.
EFFECT OF ASSAY AND BIOLOGIC VARIATION
ON DETECTION
Assay variation. In order to interpret clinically significant
changes in HIV-1 RNA levels, all sources of variability in the
quantitation of the virus were considered. Assay variability
data for plasma and patient blood samples spiked with HIV-1
were presented by industry and academic representatives. The
intrinsic variability of each RNA quantitation method (intra-
and interassay variability), independent of biological or other
variables introduced by specimen processing, was determined
over the dynamic range of the assays by using replicate samples
with different operators and different kit lots. The standard
deviation for all the kits assessed (Chiron Quantiplex [bDNA],
Roche Amplicor HIV-1 Monitor Test, and Organon Teknika
NASBA) appeared to be between 0.08 and 0.20 log10, with the
variation observed among patient samples being greater than
* Corresponding author. Mailing address: NIH/NIAID/DAIDS,
6003 Executive Blvd., Rockville, MD 20892. Phone: (301) 496-6177.
Fax: (301) 402-3684. E-mail: jl1w@nih.gov.
† Other attendees at the Technology Utilization for HIV-1 Blood
Evaluation and Standardization in Pediatrics (TUBE) workshop were
Paul Palumbo (University of Medicine and Dentistry-New Jersey Med-
ical School, Newark), Indira Hewlett (Center for Biologics Evaluation
and Research, U.S. Food and Drug Administration, Bethesda, Md.),
Richard Respess (Centers for Disease Control and Prevention, Deca-
tur, Ga.), Kenneth Rich (University of Illinois, Chicago), Jane Pitt
(Columbia Presbyterian Hospital, New York, N.Y.), and Fulvia
Veronese (Office of AIDS Research, National Institutes of Health,
Bethesda, Md.).
1471
that observed among spiked samples (2, 39). Encouragingly, a
recent study evaluating variation between the Chiron bDNA,
Roche Amplicor, and Organon Teknika NASBA assays with
patient specimens showed that the use of a common set of
HIV-1 RNA standards could eliminate differences in the esti-
mated absolute HIV-1 RNA copy number among these three
commercial tests (2).
Variability due to operator differences was presented by T.
Quinn (Fig. 1) for the Roche Amplicor assay. In this example,
there was little variation due to the operators since both were
experienced PCR technicians. However, depending upon the
proficiency of the technician, variation could be significantly
increased. This was confirmed in two recent publications which
demonstrated that interlaboratory differences were greater
than interkit differences for both spiked (39) and clinical (33)
samples.
Biological variation. Normal biological fluctuations in HIV
RNA levels can also complicate the interpretation of assay
results. There have been a few longitudinal studies on varia-
tions in HIV-1 RNA levels (13, 30, 32) in patients with rela-
tively high CD41 cell counts and other short-term studies
involving either daily variations (17) or the use of baseline
levels at initial clinical study visits (7). N. Michael presented
data on plasma RNA levels for eight untreated individuals
showing that variation was subject dependent (32). Five acutely
and three chronically infected individuals were evaluated over
324 and 1,500 days, respectively. The variation in the estimated
RNA copy number ranged from 0.25 to 1.30 log10 for the
acutely infected patients and 0.32 to 0.93 log10 for the chron-
ically infected patients. In a group analysis, biological variation
was approximately 0.35 to 0.45 log10. However, variation within
an individual may be even greater. Plasma HIV-1 RNA level
data from the Women and Infants Transmission Study have
also been examined, and preliminary analysis showed that vari-
ability in RNA levels in infants under 1 year of age was as high
as 0.70 log10, with variability appearing to be higher in younger
children than in older children.
Viral genotypic variation. Data presented suggested that the
more specific and limited the genomic region used for RNA
quantitation, the more likely it is that there will be differences
in the quantitative measurements associated with differences
in clade sequence. The Chiron bDNA assay, which assesses
a larger portion of the HIV-1 genome with multiple probes,
appeared to have fewer problems quantifying various HIV-1
subtypes than other, more target specific assays. In a study eval-
uating a limited number of RNA transcripts representing sev-
eral different clades, the Chiron bDNA assay appeared to
quantify the subtypes similarly (22). Modification of the pro-
cedures and/or the primers of other assays may improve de-
tection of different clades of HIV-1 by these assays (20). A
comprehensive set of reagents representing the various clades
will be needed to provide standards for appropriate compara-
bility studies with kits from various manufacturers.
Variation by compartment. Little is known about the varia-
tion in RNA levels in different body compartments such as
semen and cervical-vaginal secretions. R. Coombs presented
data on variations in the levels in semen over time and showed
that the variations were 5- to 10-fold higher than those ob-
served in plasma (8). Whereas reports assessing HIV-1 detec-
tion frequency in cervical-vaginal secretions have shown viral
shedding to be intermittent, very few studies specifically ad-
dressed the issue of biological variation in this particular com-
partment (21, 29).
SPECIMEN HANDLING FACTORS THAT MAY AFFECT
RNA STABILITY AND DETECTION
Blood fraction tested (plasma versus serum). The stability
of HIV-1 RNA detection in plasma versus serum was pre-
sented by S. Herman, T. Yeghiazarian, R. Carroll, B. Jackson,
and N. Michael (10, 18, 32, 37) (Table 1). Regardless of the
specific assay used, when paired samples of plasma and serum
were tested, there was a close correlation between the HIV-1
RNA levels detected in the plasma and serum specimens.
However, consistently higher viral loads were detected in
plasma samples, although the mean differences were not al-
ways statistically significant. The levels detected in plasma were
typically 30 to 80% higher than those detected in serum. Thus,
it appeared that viral load can reasonably be detected in both
plasma and serum but that individual studies should consis-
tently use either serum or plasma for RNA detection, with a
preference for plasma if possible.
Anticoagulant and time of processing. The results of numer-
ous studies on the effect of anticoagulants on viral RNA load
determinations and HIV-1 RNA stability in whole blood or
plasma are presented in Table 1. S. Herman and R. Dickover
showed that for whole blood and stored plasma specimens
collected and stored in tubes containing EDTA, about 10 to
15% and 20 to 25% more HIV-1 RNA tended to be detected
at each time point at which they were examined than was
detected in tubes containing ACD and heparin, respectively, as
determined by the Roche Amplicor assay (10). (However, such
differences are not necessarily found if a silica extraction pro-
cedure is used to prepare the specimens [see RNA Extraction
Methods for RNA Detection].) The rate of loss of detectable
RNA was greatest during the first 0 to 3 h and then 3 to 6 h
postcollection; however, this loss was less with plasma than
with whole blood. For whole-blood specimens, the amount of
RNA lost relative to the level at 1 h was about 10% for tubes
containing EDTA, 20% for tubes containing ACD, and 30%
for tubes containing heparin by 6 h. After 6 h, the viral RNA
levels in whole blood and plasma remained relatively stable at
4°C and room temperature (RT) for up to 24 to 48 h.
Data from A. Kovacs’s laboratory were also presented. Ko-
vacs and colleagues assessed (by the NASBA assay for RNA
detection) variations in RNA levels due to collection in spec-
imen tubes containing different anticoagulants, the use of dif-
ferent storage temperatures, and the timing of specimen pro-
cessing. Analysis of variance showed no statistically significant
difference in RNA levels by collection with an anticoagulant
(EDTA or ACD) or without an anticoagulant (serum), by
storage at RT or 4°C, or by processing at 0, 6, 24, or 48 h after
FIG. 1. Intraassay variability in plasma HIV-1 RNA levels for five replicates
of three samples. The Roche Amplicor Monitor assay was used to quantitate
plasma HIV-1 RNA levels (copies per milliliter) by two different experienced
technicians in separate sample runs. The mean number of RNA copies per
milliliter and the standard deviation (SD) (log10) for each sample run, by tech-
nician, are located within the columns and above the columns, respectively.
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collection. In that study, the largest decrease in RNA levels
also occurred within the first 6 h postcollection. Although not
statistically significant, collection of specimens in tubes con-
taining EDTA (versus tubes containing ACD or no anticoag-
ulant [serum]) and storage of the tubes at 4°C produced con-
sistently smaller differences in log10 RNA levels (23, 24) (Table
2).
It was postulated that the loss of RNA, seen most dramat-
ically during the first 6 h after blood collection, might be due to
the degradation of defective HIV-1 particles. Several of the
participants also suggested that the 15% less plasma RNA
signal for specimens in tubes containing ACD relative to that
for specimens in tubes containing EDTA is probably due to the
dilution factor (15%) of the ACD fluid volume in these tubes.
In summary, those studies showed that both whole blood or
plasma specimens tended to have slightly higher RNA levels
when they were collected in tubes containing EDTA rather
than tubes containing ACD or heparin and that over time
there was a relatively small loss in the amount of RNA de-
tected, with the greatest loss occurring during the first 6 h after
collection.
RNA extraction methods for RNA detection. The effect of
preextraction methods on RNA copy number was assessed by
J. Kornegay, who used the Roche Amplicor assay. Eighteen
paired plasma samples collected from HIV-infected women
were placed in tubes containing heparin and were subjected to
RNA extraction by either the silica extraction method (1) or by
using a heparinase step prior to standard RNA extraction by
the Roche Amplicor assay. The silica extraction method pro-
duced consistently higher HIV-1 RNA levels than the method
in which the plasma samples were processed with heparinase.
The yield by the heparinase method was 29% lower than that
by the silica-binding method, on average (95% confidence in-
terval 5 20 to 37%) (Fig. 2). In a separate investigation of 99
patient samples collected and placed in tubes containing hep-
arin and 11 samples collected and placed in tubes containing
EDTA, no significant differences in RNA levels were seen
when the silica extraction method was used for all extractions
prior to testing by the Roche Amplicor assay (3). These ob-
servations suggest that the method of RNA extraction can have
an important effect on the quantitation of RNA, and specifi-
cally, use of silica extraction prior to detection by the Roche



































































































































































































































































































































































































































































































TABLE 2. Difference in HIV-1 RNA levels from baseline





Mean 6 SD log10 difference in HIV-1 RNA levels
from baseline levels at the following times:
6 h 24 h 48 h
EDTA RT 7 10.066 6 0.200 10.085 6 0.237 10.114 6 0.259
4°C 7 20.001 6 0.310 20.077 6 0.278 20.060 6 0.336
ACD RT 7 20.194 6 0.309 20.216 6 0.083 20.180 6 0.286
4°C 7 10.057 6 0.171 20.108 6 0.268 20.119 6 0.311
Serum RT 5 20.280 6 0.419 20.064 6 0.606 20.092 6 0.388
4°C 7 20.007 6 0.260 20.076 6 0.315 20.061 6 0.349
Total 40 20.049 6 0.278 20.077 6 0.313 20.044 6 0.320
a Analysis of variance showed no statistical significant difference by type of
anticoagulant or temperature at each time point. The total number of samples
was 160; the total number of patients was 7. The Organon Teknika NASBA assay
was used for testing.
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Long-term storage (temperature and time). RNA in plasma
appeared to be stable for extended periods of time, particularly
when it was stored at 280°C. Using the Chiron bDNA assay
for detection, T. Yeghiazarian presented data from a study
in which the differences between the RNA levels detected in
specimens (samples with relatively high viral loads diluted in
HIV-1-negative plasma) stored at 220 or 280°C for 80 weeks
were evaluated (37). After 12 weeks of storage, a decline in
RNA levels detected in samples stored at 220°C versus those
stored at 280°C was noted, although the difference was not
significant. However, by weeks 20 to 24, the difference in RNA
levels in samples stored at 220°C versus the RNA levels in
samples stored at 280°C became statistically significant, with
specimens stored at 280°C having 30 to 80% more RNA than
those stored at 220°C.
S. Herman presented data suggesting that storage of plasma
for 10 years at 220°C and storage of serum for 4 to 7 years at
270°C appeared to have no significant effect on relative RNA
quantitation by the Roche Amplicor assay. L. Mofenson re-
ported on data from the National Institute of Child Health and
Development IVIG Clinical Trial in which HIV RNA levels in
254 stored baseline serum samples from children enrolled in
the study between 1988 and 1990 were assessed in 1996 by the
NASBA assay (thus, the samples were stored for 6 to 9 years
prior to testing). There was a similar distribution of values
(over a 4-log range in HIV-1 RNA copy number) and no sig-
nificant differences in geometric mean and median RNA lev-
els, regardless of the year of study entry (28) (Fig. 3).
In another recent study with 10 specimens collected in tubes
containing EDTA, ACD, or heparin and stored for 6 months
prior to testing by the NASBA assay, the results indicated that
the mean viral loss due to storage was within the expected
variance of the assay (14). The findings of all these studies
suggest that appropriate long-term storage does not have a
significant effect on detectable HIV-1 RNA levels.
Freeze-thaw cycles. Repeated freeze-thaw cycles of plasma
samples stored at 220 and/or 280°C were evaluated by S.
Herman, T. Yeghiazarian, R. Carrol, B. Weiser, and S. Fiscus
(10, 11, 37). There was an insignificant loss of RNA levels after
one to four freeze-thaw cycles (Table 1). For example, S. Her-
man showed that the amount of HIV-1 RNA detected (by the
Roche Amplicor assay) after two to four freeze (at 280°C)-
thaw cycles as a percentage of the amount detected after the
first freeze-thaw cycle for eight plasma specimens processed
from tubes containing either ACD or EDTA averaged from
about 120 to 150% (10). By the NASBA assay, Ginochio et al.
(14) showed that the levels of HIV-1 RNA in 10 plasma spec-
imens collected in tubes containing EDTA, ACD, or heparin
after one freeze (at 270°C)-thaw cycle had a mean loss that
was insignificant (14). In addition, although T. Yeghiazarian
showed that three freeze (at 220°C)-thaw cycles produced a
statistically significant decrease (about 20%) in HIV-1 RNA
levels from the levels detected after only one freeze-thaw cycle,
the decrease was within the expected variation of the Chiron
bDNA assay used. No significant decrease was seen for spec-
imens stored at 280°C; however, this could have been due to
the lower baseline levels detected after one freeze (at 280°C)-
thaw cycle (Fig. 4). Similar results were obtained regardless of
the conditions of the freezing (at 280°C)-thawing, e.g., imme-
diate sample processing with short thaw periods and quick
freezing (presented by T. Yeghiazarian) to thawing at RT over
20 min or in a 37°C water bath for 10 min (presented by B.
Weiser).
Shipping. Comparison of RNA copy numbers in samples
from local and distantly located sites showed that there were
no significant differences. S. Herman presented comparative
data on 25 patient specimens collected in tubes containing
EDTA or ACD, separated into plasma, and shipped overnight
FIG. 2. Comparison of two RNA extraction methods, heparinase treatment
and silica-binding extraction, on HIV-1 RNA copy number detected by the
Roche Amplicor Monitor assay.
FIG. 3. Geometric mean baseline HIV-1 RNA level by year of study entry.
The collected blood specimens were separated, and the serum was initially stored
at 220 or 270°C prior to periodic shipment to a central repository. Serum
specimens were stored centrally at 270°C for 4 to 7 years prior to batch testing
by the Organon Teknika NASBA assay (28).
FIG. 4. Percent difference in HIV-1 RNA detection between one and three
freeze-thaw cycles. The RNA equivalents per milliliter after the first freeze-thaw
cycle, which is considered the baseline value, are given beneath the white col-
umns (freezing at 220°C) and beneath the black columns (freezing at 280°C;
numbers in brackets). HIV-1 RNA was detected by the Chiron bDNA assay (37).
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either on dry ice with cold packs (2 to 8°C) or at ambient
temperature (10). Median RNA values (by the Roche Ampli-
cor assay), expressed as a percentage of the median RNA level
in samples shipped on dry ice, were 98% for specimens in tubes
containing EDTA and 100% for specimens in tubes containing
ACD for specimens shipped with cold packs and 90% for
specimens in tubes containing EDTA and 80% for specimens
in tubes containing ACD for specimens shipped at ambient
temperature. Shipping of plasma specimens overnight at am-
bient temperature did not appear to decrease the detectable
HIV RNA levels in comparison to the levels in local specimens
that were quickly processed. S. Fiscus compared the RNA
concentrations in the plasma of 25 perinatally HIV-1 infected
infants using the NASBA assay; 11 infants were local to the
study site and 14 infants were seen at clinics 75 to 300 miles
away. The local plasma specimens were centrifuged and were
frozen within 3 h of phlebotomy and had a median of 5.80 log10
RNA copies/ml (interquartile range, 5.56 to 6.40 log10 RNA
copies/ml). The plasma samples which were shipped overnight
at ambient temperature had a median of 5.63 log10 RNA
copies/ml (interquartile range, 5.32 to 6.28 log10 RNA copies/
ml).
M. Robb reported on the use of a laboratory-specific HIV-1
RNA assay (38) with serum specimens from adult and pediat-
ric patients enrolled in different U.S. cohort studies that had
been under long-term storage. These specimens were trans-
ported at room temperature prior to processing and arrived
within 6 h of collection in most cases. Some samples were
drawn at distant locations and were shipped overnight at room
temperature prior to processing. Forty-nine maternal samples
were analyzed, and 20 of these were drawn at locations requir-
ing overnight shipment. The comparison of local and distantly
acquired samples showed no differences in HIV-1 RNA levels
in locally obtained samples and those whose processing was
delayed (Table 3).
Effects of other factors on viral load detection. The effects of
common antimicrobial agents in plasma samples, hemolysis,
lipidemia, and elevated bilirubin levels on the HIV-1 RNA
load detected by the Chiron bDNA assay were presented by T.
Yeghiazarian (37). HIV-1-positive and HIV-1-negative plasma
samples were spiked with (i) one of three pools of antimicro-
bials agents, one of two levels of hemoglobin (0.5 and 1.0
mg/ml), or (iii) 10 mg of bilirubin per dl. None of the sub-
stances interfered with the determination of the RNA copy
number or gave false-positive results for the HIV-1-negative
samples. Additionally, visible lipidemia was not found to alter
the RNA levels in HIV-1-positive plasma samples.
ALTERNATE TESTING METHODS
In addition to the information presented on techniques for
evaluation of plasma RNA levels, the workshop also reviewed
data on some promising alternate testing methods. These in-
cluded evaluation of HIV-1 RNA levels by using dried plasma
spots (DPSs) on filter paper and methods for the detection of
HIV-1 RNA levels in semen and cervical-vaginal secretions.
DPSs on filter paper. The feasibility of using DPSs for the
quantitation of viral RNA and comparison of the results ob-
tained with DPSs to those obtained by standard assays of
plasma were described by S. Cassol (5). The effects of field
conditions including humidity and temperature and the effects
of short-term storage were assessed. Retrospective analysis of
51 paired specimens of cryopreserved plasma and DPS by a
commercial assay (Roche Amplicor) indicated that the HIV-1
RNA levels from DPSs were equivalent to those obtained from
fresh frozen plasma. The RNA levels obtained by assays with
DPSs stored under different field conditions appeared to be
stable. There was no evidence of a decline in RNA levels when
the DPSs were stored at refrigerated or ambient temperature
for up to 16 days or at 37°C for 3 days. Use of DPS specimens
would be particularly useful for evaluating HIV-1 RNA levels
in field trials in settings where the capacity for specific sample
processing and refrigeration or freezing are not readily avail-
able.
S. Cassol also presented data for direct automated sequenc-
ing of viral DNA from dried blood spots (DBSs) for the de-
tection of HIV-1 env subtypes A, B, C, and E (6). Results were
presented for 51 DBSs from mostly asymptomatic HIV-1-in-
fected individuals from five Asian countries. These specimens
were shipped without refrigeration and were stored for more
than 2 years. The subtypes identified were primarily subtype C
with a few subtype A in India and subtypes B and E in Thai-
land, China, and Indonesia. Thus, the DBSs appeared to offer
a practical approach for the genetic surveillance of the HIV-1
isolates from different populations, including recent serocon-
verters and vaccine trial participants.
Semen and cervical-vaginal specimens. A comparison of use
of the Roche Amplicor and NASBA assays with seminal fluid
was presented by S. Fiscus (11). Results from the two assays,
expressed in terms of RNA copy number per milliliter of ejac-
ulate, suggested that the detection of RNA in seminal fluid was
complicated by the presence in semen of nonspecific inhibitors
which interfere with the PCR step and that these inhibitors
were removed by the use of the silica extraction method used
in the NASBA assay. In addition, the HIV-1 RNA levels in
seminal fluid samples were stable through at least four freeze-
thaw cycles in that study.
One of the major problems associated with the quantifica-
tion of HIV-1 RNA from cervical-vaginal secretions is that
most such specimens are collected as a cervical-vaginal lavage
and there is no standard method dealing with the dilution
effect for a lavage specimen that may be only partially re-
trieved. R. Coombs presented data on the use of a “sno-strip”
method (Akorn Inc., Abita Springs, La.) for the detection of
HIV-1 RNA in cervical specimens. This method circumvents
this obstacle by directly wicking up known quantities of cell-
free cervical-vaginal fluid onto filter paper (8).
Data from Kovacs’ laboratory was presented on the effect of
time to processing and the best sample type (whole cervical-
vaginal lavage specimen, supernatant or cell pellet) to detect
and quantitate HIV-1 RNA by the NASBA assay. In that
study, 27 cervical-vaginal lavage specimens from 9 HIV-posi-
tive women were refrigerated (4°C) after collection, processed
as whole cervical-vaginal lavage specimens at 0, 3, 6, and 24 h
TABLE 3. Difference in HIV-1 RNA levels between
local and distant serum specimensa
Measurement
Mean log10 difference in HIV-1 RNA levels







Mean 3.042 2.904 3.136
Median 3.298 3.158 3.428
Range 4.030 3.650 4.030
SD 1.193 1.043 1.296
a Local, specimens that were transported at room temperature prior to pro-
cessing which generally took place within 6 h of collection; distant, specimens
that were transported at RT via overnight delivery prior to processing. HIV-1
RNA levels were determined by the liquid hybridization PCR assay (38).
VOL. 36, 1998 MINIREVIEW 1475
after collection, and centrifuged and separated into a super-
natant and a cell pellet. Cervical-vaginal lavage samples stored
at 4°C appeared to be stable for up to 24 h with no significant
difference in log10 RNA levels in either whole cervical-vaginal
lavage samples or the supernatant over time. Significantly
more HIV-1 RNA was detected in whole cervical-vaginal la-
vage samples and cell pellets compared to the levels obtained
in the supernatant (Table 4) (23, 24). Lastly, W. Meyer pre-
sented results for unfractionated frozen cervical-vaginal lavage
fluids collected and processed in a routine manner by the
NASBA technique for the detection of HIV-1 RNA. There
appeared to be an inverse relationship between the detection
of HIV-1 RNA in cervical-vaginal lavage specimens and the
peripheral CD4 count, and the HIV-1 RNA levels detected in
plasma generally exceeded the quantity detected in cervical-
vaginal lavage specimens. Although the results of these limited
studies with genital fluids are encouraging, understanding of
the role of HIV-1 in these compartments will require further
development of acceptable and standardized techniques for
assay usage and specimen collection.
RECOMMENDATIONS FOR TESTING OF PERIPHERAL
BLOOD FOR HIV RNA IN PEDIATRIC STUDIES
National studies. Workshop participants felt that although
some studies have been published (22, 34), there remains an
urgent need for further data to obtain a better understanding
of the association between plasma HIV-1 RNA levels and
disease progression in pediatric patients of different ages. Such
studies were considered to be of the highest priority.
The potential of HIV-1 RNA detection as a diagnostic assay
for HIV-1 infection in young infants was discussed. Although it
was agreed that the “gold standards” for the detection of
HIV-1 infection in children born to HIV-1-positive mothers
are HIV-1 culture and/or positivity for HIV-1 DNA by PCR,
theoretically, HIV-1 RNA can be detected before HIV-1 is
detected by the other two tests. The level of HIV-1 RNA at the
time of early detection might also be valuable in identifying the
potential for disease progression. Thus, studies validating the
detection of HIV-1 RNA as a diagnostic marker were consid-
ered an important priority, albeit secondary to that of validat-
ing HIV-1 RNA detection as a surrogate marker for disease
progression.
On the basis of data presented at the workshop, the session
participants also concluded that (i) of the various assays for the
detection of HIV-1 RNA evaluated, one assay did not appear
to be significantly superior to the others when considering spe-
cimen-handling techniques; (ii) further data are needed regard-
ing the natural history of HIV-1 RNA in children and the
correlation of the presence of HIV-1 RNA with clinical out-
come and the response to therapy in pediatric patients; and
(iii) data regarding HIV-1 RNA in adolescents (an important
but distinct subset of pediatric patients) are needed to deter-
mine if pubertal changes modify the natural history of RNA in
these patients.
The research priorities for the use of assays for the detection
of HIV-1 RNA in pediatric HIV studies in the United States
and the methods best suited to the collection, processing, ship-
ping, and analysis of study specimens are summarized in Table
5. It was generally agreed by the participants that standardiza-
tion of specimen handling and assay performance is important
for the interpretation of the results. However, the information
presented at the workshop suggested that a reasonable range
of variability in these parameters could be acceptable, and this
was reflected in the guidelines for specimen handling pre-
sented in Table 5.
International studies. The application of viral burden assays
in developing countries poses unique challenges. Costly viral
burden assays are not likely to play a major role in the medical
management of HIV-1-infected patients in countries with lim-
ited resources. Rather, viral burden assays should be optimized
to meet the research agenda of developing countries, which
currently focuses on the more economically feasible goal of
prevention. Differences among the clades of HIV-1 must be
strongly considered in this setting; thus, such technical chal-
lenges to assays must be considered along with field conditions
that depart significantly from the conditions found in clinics
and laboratories in the developed world, and cultural sensibil-
ities regarding phlebotomy volume and frequency must be
respected.
In general, processing techniques should be simple and should
be reliable in extremes of temperature and humidity. For these
reasons, many experts at the meeting endorsed the use of DBSs
or DPSs collected on filter papers. New collection tubes which
are designed to separate plasma and cells and optimize the
biological integrity of both, despite delayed processing after
phlebotomy, are available. Alternatively, plasma, serum, and
cells may be separated on-site by standard techniques and
stored on liquid nitrogen, which is often more widely and
reliably available than dry ice or high-quality freezers. How-
ever, all collection and storage devices may not perform as
expected when they are deployed in less developed settings due
to differences in the study population or the physical setting.
For example, an endemic parasitic disease producing anemia
may degrade the performance of cell separator collection de-
vices. As a consequence, an element of the research designs in
these settings must include revalidation of the techniques es-
tablished in the developed world. Equipment requirements
should be minimized to the extent possible, and equipment
should be reliable in the setting of fluctuating availability of
electrical power and environmental extremes. For example, the
use of nonrefrigerated, fixed-angle centrifuges in assays de-
ployed for use worldwide would be a significant advantage.
In view of the emphasis on HIV-1 transmission research in
developing countries, the desire for viable peripheral blood
mononuclear cells for functional studies, viral isolation, and
flow cytometric studies may require the use of alternative anti-
coagulants such as heparin or ACD. Since the stability of cell-
free RNA appears to be superior in tubes containing EDTA, it
is likely that no single collection device will suffice for most
TABLE 4. Stability of HIV-1 RNA copies per milliliter detected in
unseparated (whole) and separated (supernatant) cervical-vaginal
lavage specimens processed at different timesa
Specimen
no. Specimen
No. of HIV-1 RNA copies/ml at
the following times:
0 h 3 h 6 h 24 h
1 Whole 42,000 60,000 15,000 31,000
2 Whole 3,600 1,700 1,700 1,500
3 Whole 14,000 8,500 6,000 5,400
4 Whole 3,800 100 100 100
5 Whole 25,000 33,000 21,000 9,600
1 SUP 5,600 11,000 4,600 4,100
2 SUP 1,800 2,000 1,200 940
3 SUP 3,200 3,500 2,400 1,600
4 SUP 100 100 100 100
5 SUP 100 100 100 100
a Specimens were stored at 4°C prior to processing (separation) and were
tested by the Organon Teknika NASBA assay (23, 24). SUP, supernatant.
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study needs. Future research should emphasize the develop-
ment of collection tubes which provide biologically intact cells
and stable cell-free RNA in plasma and which require only
simple management efforts in the field. In addition, processing,
storage, and transport paradigms need to be a focus of efforts
in environments different from those present in the United
States and Europe. A summary of the recommendations for
studies with HIV-1-infected pediatric subjects in relationship
to laboratory assay and specimen-handling issues in the inter-
national setting are presented in Table 5.
SUMMARY AND CONCLUSIONS OF WORKSHOP
Appropriate interpretation of HIV-1 RNA levels requires
an understanding of differences in test results due to multiple
factors, which include assay and biological variation as well as
specimen-handling conditions. Multiple investigations with di-
verse patient populations and assays have suggested that the
contributions of technical and biological variations to RNA
levels were quite consistent and predictable and in the range of
0.3 to 0.6 log10 RNA copies/ml. To date, all of the studies that
have assessed variations in the levels of HIV-1 RNA measured
have been limited primarily to isolates of the B clade; thus,
what is lacking is knowledge of the degree to which the clade
subtype influences assay variation and whether the biological
variation observed with the clade B subtype is consistent for
other clades.
The major finding from the workshop was the unexpected
stability of the HIV-1 RNA collected and stored under a va-
riety of specimen handling conditions. HIV-1 RNA was shown
to be relatively stable in whole blood, plasma, and serum, with
the greatest stability being in plasma. Separated plasma was
TABLE 5. Recommendations for handling of blood samples to be assayed for HIV-1 RNA with U.S. and international research cohorts
Area receiving recommendation Research studies with U.S. cohorts Research studies with international cohorts
I. Research priorities for HIV RNA testing 1. Validate use as a predictor of disease progression in
pediatric patients
1. Infant HIV diagnosis for assessment of early
efficacy results from perinatal prevention trials
2. Evaluate as a diagnostic assay for HIV infection in
young infants
2. Measurement in plasma, cervical-vaginal secre-
tions, and breast milk to evaluate mechanisms
of perinatal HIV-1 transmission
3. Study of breakthrough in vaccine recipients
4. Pathogenesis studies of cofactors and clade
differences related to disease progression
II. Component of blood used, specimen
collection tube
1. Plasma is preferable to serum, but consistency is most
important
1. Both cells and plasma be collected and
stored
2. Tubes containing EDTA were preferable to those
containing ACD, followed by those containing
heparina
2. Ideally, at a minimum samples would be col-
lected in two tubes: (i) a tube containing EDTA
would be used for plasma RNA and flow stud-
ies; (ii) tubes containing CPT, heparin, or ACD
would be used depending on the research
study and on-site laboratory capabilities.
III. Timing of specimen processing 1. Process (i.e., spin and separate) whole blood between
3 and 6 h after collection, particularly if the specimen
is collected in a tube containing ACD
1. Ideally, the separation of plasma and cells was
recommended to be done between 4 and 6 h
but up to 24 to 48 h after specimen collection
2. For specimens in tubes containing EDTA or other
anticoagulants, processing could occur up to 24 h af-
ter collection
IV. Stability and storage conditions 1. For whole blood, store the specimen at RT for up to
24 h if culture or lymphocyte function assays are not
planned; otherwise, store at 4°C for up to 24 h until
processing.
1. Both cells and plasma should be frozen and
stored in liquid nitrogen, given problems with
electricity outages and 270°C freezers
2. For plasma specimens, store at 4°C for up to 5 days,
although storage at 270°C indefinitely is ideal, fol-
lowed by storage at 220°C for up to 20 wk
V. Shipping conditions 1. Ship whole blood or plasma specimens within 24 h of
sample collection; temperature extremes should be
avoided by using an insulated container to pack and
ship the specimens; freezing of whole blood should be
avoided to preserve CD4 cells
1. Shipments should be on dry ice
2. Plasma specimens can be sent at RT or 4°C or frozen
VI. Future studiesb 1. Future technical studies should focus on use of dried
plasma spots for quantitative RT-PCR in plasma
1. Separation techniques applicable to developing
country settings need to be validated
2. Field deployable rapid diagnostic tests 2. Future technical studies should focus on the
use of dried plasma spots for quantitative
RT-PCR in plasma
3. Development of assays that will detect multiple
HIV clades well and a standardized panel of
different clades of viruses for testing the assays
a If a silica extraction method for RNA is used prior to testing by the Roche Amplicor Monitor assay, then there may be less concern regarding which anticoagulant
is used.
b Also see research priorities.
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found to have stable titers even after storage at room temper-
ature for 24 to 48 h and repeated freeze-thaw cycles. Within
the constraints of the studies described here, the potential
differences in RNA levels due to various specimen-handling
conditions were not large (10 to 20% due to the anticoagulant
type used in the collection tube [30 to 80% if serum rather than
plasma is used], 10 to 30% due to time at RT prior to process-
ing within 24 h, 30 to 80% due to the use of a storage temper-
ature of 220 or 280°C). Thus, the anticipated RNA levels for
nonideally collected and processed plasma specimens may be
only about 130% (0.11 log10) less than those for plasma spec-
imens collected and processed ideally (assuming that these
differences are additive). This 130% difference is relatively
small compared to the potential total average standard devia-
tion of up to about 400% or 0.6 log10 RNA copies/ml due to
intra- and interassay (both 0.1 to 0.2 log10) and biological (0.1
to 0.2 log10) RNA copies/ml factors. On the basis of these
findings, workshop participants concluded that retrospective
studies, including those which have used sera or heparinized
samples, should show biological comparability to studies per-
formed under ideal conditions, and thus both retrospective and
prospective studies are useful in providing an understanding of
the role of HIV-1 RNA levels in blood in transmission and
disease progression. However, for prospectively designed stud-
ies, workshop participants recommended that blood for quan-
titative HIV-1 RNA testing ideally be collected in tubes con-
taining EDTA, processed within 6 h of collection (but up to
24 h is still acceptable), and then stored at 280°C until assayed.
Novel methodological approaches which could be useful in
diagnosing and quantitating viral load in developing countries
were also described, i.e., the use of DPSs, or in other body
fluids such as cervical-vaginal secretions, i.e., sno-strip wicks.
Finally, workshop participants determined what laboratory
evaluations, including assays of HIV-1 RNA levels, with blood
samples should be a priority in pediatric cohort studies while
acknowledging that this ultimately depends on the study ques-
tion being asked. Recommendations concerning specimen
handling were then developed for international and domestic
studies that use assays for detection of HIV-1 RNA.
The findings reported herein underscore the continued need
for the exchange of information among investigators and in-
dustry with the aim of elucidating the technological parameters
that influence the assays used to evaluate HIV-1 disease and
therapeutic interventions. Only by understanding the factors
that affect assay outcome can we appropriately discern their
value and use in clinical studies and for patient management.
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